University of Toronto receives $35 million to modernize high containment facility.
Welcome to EPIC – The Emerging and Pandemic Infections Consortium.
EPIC Partners play an integral role in infectious disease research, from work that controlled diphtheria and helped eradicate smallpox 100 years ago, to current research in antimicrobial resistance and infection control.
Today, our collective fight against infectious threats, including COVID-19, highly pathogenic avian influenza and mpox, makes clear that there’s never been a more important time to advance EPIC – the Emerging and Pandemic Infections Consortium as a critical hub in the pan-Canadian effort to combat future pandemics.
Building on our momentum in combatting the SARS-CoV-2 virus, EPIC will marshal the advanced research infrastructure and the world-renowned research and training expertise of the EPIC Partners to allow an integrated innovative response to infectious diseases.
EPIC is a collaborative initiative among:
- University of Toronto
- The Hospital for Sick Children (SickKids)
- Lunenfeld-Tanenbaum Research Institute
- Sunnybrook Research Institute
- University Health Network
- Unity Health Toronto
These globally-leading institutions will make a difference to preventing the next pandemic and enhancing the impact of the life sciences ecosystem in Ontario.
These are the four pillars of EPIC’s work
Toronto High Containment Facility
Toronto’s only Combined Containment Level 3 (C-CL3) facility for the study of high-risk human pathogens has been critical to understanding the viral pathogens and developing therapeutics and treatments. Infectious diseases continue to pose a threat to Canadians’ health and prosperity. Investments in the facility will prepare Ontario and Canada for future pandemics.
Training & Talent
EPIC offers immersive and cross-disciplinary training to a diverse cohort of talent researching infectious diseases, who are ready to work in industry and academia. Hundreds of researchers, clinicians and lab staff will gain access to leading-edge technologies, develop the skills to turn discovery into solutions, and connect Canada to global networks of pandemic surveillance and response.
Transformative Research
EPIC will connect multiple disciplines to address infectious diseases. Insights made possible by state-of-the-art platforms that accelerate the discovery and production of therapies will combine with the expertise of clinicians, engineers, public health experts and scientists to translate treatments to patients and improve their outcomes.
Knowledge Translation
EPIC will play an important role as a knowledge broker. It will create a hub for potential commercialization of novel therapeutics. New researchers at EPIC will be equipped to explain bench science to decision-makers and the public, as well as to translate discoveries into made-in-Canada products and solutions to global health challenges.
84 weeks
Estimated number of weeks required to clear surgery backlogs in Ontario.
%
$26B
Amount (in Billions) that Canada’s federal government is targeting for health and biosciences exports by 2025.
EPIC News
Expanding the research toolbox for one of the world’s deadliest animals
Mosquito-transmitted diseases affect an estimated 347.8 million people annually and are responsible for nearly 450,000 deaths each year, making them one of the most dangerous animals in the world. Despite their devastating impact, research on the mosquito has lagged behind that of other model organisms, in part due to the lack of appropriate tools and resources. Kathryn Rozen-Gagnon is trying to change that. Read more about how she is integrating diverse fields to study the interplay between mosquito-borne viruses and their mosquito and human hosts.
Expanding the research toolbox for one of the world’s deadliest animals
Mosquito-transmitted diseases affect an estimated 347.8 million people annually and are responsible for nearly 450,000 deaths each year, making them one of the most dangerous animals in the world. Despite their devastating impact, research on the mosquito has lagged behind that of other model organisms, in part due to the lack of appropriate tools and resources. Kathryn Rozen-Gagnon is trying to change that. Read more about how she is integrating diverse fields to study the interplay between mosquito-borne viruses and their mosquito and human hosts.
Member Spotlight: Jean-Philippe Julien
A conversation with with Jean-Philippe Julien, a senior scientist in the molecular medicine program at SickKids Research Institute and an associate professor in the departments of biochemistry and immunology in the Temerty Faculty of Medicine at the University of Toronto. He also holds the Canada Research Chair in Structural Immunology.
The Canada-Africa Mpox Partnership launches with $3 million team grant
Researchers from the University of Toronto and Nigerian Institute of Medical Research have received $3 million from the federal government to launch an international project that will help inform the clinical and public health response to local and global epidemic of mpox. The new funding from the Canadian Institutes of Health Research (CIHR) and International Development Research Centre builds on the collaborative projects and seed funding from the mpox rapid research response launched by EPIC earlier this year.